[
  {
    "date": "2023-07-30",
    "symbol": "RFL",
    "period": "FY",
    "cashandcashequivalentsatcarryingvalue": 21498000,
    "availableforsalesecuritiesdebtsecuritiescurrent": 57714000,
    "accountsandotherreceivablesnetcurrent": 387000,
    "convertiblenotereceivablerelatedparty": 1921000,
    "receivablesnetcurrent": 213000,
    "prepaidexpenseandotherassetscurrent": 914000,
    "equitysecuritiesfvni": 294000,
    "assetscurrent": 82941000,
    "propertyplantandequipmentnet": 1695000,
    "investmentsandothernoncurrentassets": 65000,
    "inprocessresearchanddevelopment": 1575000,
    "otherassetsnoncurrent": 9000,
    "assets": 98829000,
    "accountspayablecurrent": 333000,
    "accruedliabilitiescurrent": 763000,
    "otherliabilitiescurrent": 1023000,
    "liabilitiescurrent": 2145000,
    "otherliabilitiesnoncurrent": 55000,
    "liabilities": 2200000,
    "commonstockvalueoutstanding": 8000,
    "additionalpaidincapitalcommonstock": 264010000,
    "retainedearningsaccumulateddeficit": -167333000,
    "accumulatedothercomprehensiveincomelossavailableforsalesecuritiesadjustmentnetoftax": -353000,
    "accumulatedothercomprehensiveincomelossforeigncurrencytranslationadjustmentnetoftax": 3725000,
    "stockholdersequity": 100293000,
    "minorityinterest": -3664000,
    "stockholdersequityincludingportionattributabletononcontrollinginterest": 96629000,
    "liabilitiesandstockholdersequity": 98829000,
    "allowancefordoubtfulaccountsreceivablecurrent": 245000,
    "commonstockparorstatedvaluepershare": 0.01,
    "commonstocksharesauthorized": 35000000,
    "commonstocksharesissued": 787163,
    "commonstocksharesoutstanding": 787163,
    "revenues": 171000,
    "generalandadministrativeexpense": 8932000,
    "researchanddevelopmentexpense": 6312000,
    "depreciationandamortization": 78000,
    "operatingincomeloss": -15043000,
    "interestincomeother": 3253000,
    "impairmentofinvestments": 334000,
    "marketablesecuritiesrealizedgainlossexcludingotherthantemporaryimpairments": 154000,
    "realizedinvestmentgainslosses": 309000,
    "marketablesecuritiesunrealizedgainloss": 33000,
    "unrealizedgainlossoninvestments": 2663000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -8745000,
    "incometaxexpensebenefit": -255000,
    "incomelossfromequitymethodinvestments": 203000,
    "incomelossfromcontinuingoperationsincludingportionattributabletononcontrollinginterest": -8693000,
    "discontinuedoperationincomelossfromdiscontinuedoperationduringphaseoutperiodnetoftax": -306000,
    "discontinuedoperationgainlossondisposalofdiscontinuedoperationnetoftax": 6784000,
    "incomelossfromdiscontinuedoperationsnetoftax": 6478000,
    "profitloss": -2215000,
    "netincomelossattributabletononcontrollinginterest": -339000,
    "netincomeloss": -1876000,
    "othercomprehensiveincomeunrealizedholdinggainlossonsecuritiesarisingduringperiodnetoftax": -290000,
    "othercomprehensiveincomeforeigncurrencytransactionandtranslationgainlossarisingduringperiodnetoftax": -42000,
    "comprehensiveincomenetoftaxincludingportionattributabletononcontrollinginterest": -2547000,
    "comprehensiveincomenetoftaxattributabletononcontrollinginterest": -336000,
    "comprehensiveincomenetoftax": -2211000,
    "incomelossfromcontinuingoperationsperbasicshare": -0.36,
    "incomelossfromdiscontinuedoperationsnetoftaxperbasicshare": 0.28,
    "earningspersharebasic": -0.08,
    "weightedaveragenumberofsharesoutstandingbasic": 23263211,
    "incomelossfromcontinuingoperationsperdilutedshare": -0.36,
    "incomelossfromdiscontinuedoperationsnetoftaxperdilutedshare": 0.28,
    "earningspersharediluted": -0.08,
    "weightedaveragenumberofdilutedsharesoutstanding": 23263211,
    "stockissuedduringperiodvaluesharebasedcompensation": 2000,
    "stockissuedduringperiodsharessharebasedcompensation": 220019,
    "stockissuedduringperiodvaluerestrictedstockawardforfeitures": 2000,
    "stockissuedduringperiodsharesrestrictedstockawardforfeited": 296759,
    "stockissuedduringperiodvalueemployeestockpurchaseplan": 1000,
    "stockissuedduringperiodsharesemployeestockpurchaseplans": 120697,
    "stockissuedduringperiodvalueacquisitions": 16000,
    "foreigncurrencytransactiongainlossbeforetax": -42000,
    "incomelossfromdiscontinuedoperationsnetoftaxattributabletononcontrollinginterest": 6478000,
    "incomelossfromcontinuingoperations": -8693000,
    "depreciationdepletionandamortization": 78000,
    "gainlossoninvestmentshedgefund": 220000,
    "unrealizedgainoninvestmentscyclotherapeuticsinc": -2663000,
    "gainlossonsaleofproperties": 1195000,
    "equityinlossofdaythreelabsinc2": 203000,
    "provisionfordoubtfulaccounts": 110000,
    "sharebasedcompensation": 2188000,
    "increasedecreaseinaccountsandotherreceivables": 117000,
    "increasedecreaseinotherreceivables": 247000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -373000,
    "increasedecreaseinotheroperatingassets": 27000,
    "increasedecreaseinaccountspayableandaccruedliabilities": -827000,
    "increasedecreaseinothercurrentliabilities": 781000,
    "increasedecreaseinduetorelatedpartiescurrent": -43000,
    "increasedecreaseinothernoncurrentliabilities": 15000,
    "netcashprovidedbyusedinoperatingactivitiescontinuingoperations": -10247000,
    "cashprovidedbyusedinoperatingactivitiesdiscontinuedoperations": -639000,
    "netcashprovidedbyusedinoperatingactivities": -10886000,
    "paymentstoacquireavailableforsalesecuritiesdebt": 204798000,
    "proceedsfromsaleofheldtomaturitysecurities": 185121000,
    "paymentsforproceedsfromloansreceivable": 2000000,
    "proceedsfrominvestmentsotherpharmaceuticals": 78000,
    "paymentstoacquireequitysecuritiesfvni": 1586000,
    "proceedsfromsaleandmaturityofmarketablesecurities": 1325000,
    "paymentstoacquireshortterminvestments": 3000000,
    "purchaseofinvestmentincyclotherapeuticsinc": 2100000,
    "netcashprovidedbyusedininvestingactivitiescontinuingoperations": -26960000,
    "cashprovidedbyusedininvestingactivitiesdiscontinuedoperations": 48171000,
    "netcashprovidedbyusedininvestingactivities": 21211000,
    "paymentsfortaxesrelatedtoshareswithheldforemployeetaxes": 218000,
    "netcashprovidedbyusedinfinancingactivitiescontinuingoperations": -218000,
    "cashprovidedbyusedinfinancingactivitiesdiscontinuedoperations": -15000000,
    "netcashprovidedbyusedinfinancingactivities": -15218000,
    "effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalents": -146000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -5039000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 21498000,
    "acquisitionofadditionalownershipinterestinlipomedix": 16000,
    "liquiditypolicypolicytextblock": "Liquidity",
    "convertiblenotereceivablerelatedpartypolicytextblock": "Convertible Note Receivable, Related Party",
    "investmentshedgefundspolicytextblock": "Investments - Hedge FundsThe Company accounts for its investments in hedgefunds in accordance with ASC 321, Investments – Equity Securities. Unrealized gains and losses resulting from the changein fair value of these securities is included in unrealized (loss) gain on investments – Hedge Funds in the consolidated statementsof operations and comprehensive loss.",
    "corporatebondsandustreasurybillspolicypolicytextblock": "Corporate Bonds and US Treasury Bills",
    "costmethodinvestmentpolicypolicytextblock": "Cost Method Investment",
    "assetsheldforsaleanddiscontinuedoperationspolicytextblock": "Assets Held-for-Sale and Discontinued Operations",
    "debtissuancecostspolicytextblock": "Debt Issuance Costs",
    "scheduleofallmajorityownedsubsidiariesareconsolidatedtabletextblock": "All majority-owned subsidiaries are consolidatedwith all intercompany transactions and balances eliminated in consolidation. In addition to Rafael Holdings, Inc., the subsidiaries includedin these consolidated financial statements are as follows:",
    "scheduleoflonglivedassetstabletextblock": "Equipment, buildings, leasehold improvements,and furniture and fixtures are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives, whichrange as follows:",
    "subsidiaryorequitymethodinvesteenatureofoperations": "United States – Delaware",
    "subsidiaryorequitymethodinvesteecumulativepercentageownershipafteralltransactions": 1,
    "propertyplantandequipmentusefullife": "P40Y",
    "buildingsandimprovementsgross": 2505000,
    "propertyplantandequipmentother": 68000,
    "propertyplantandequipmentgross": 2573000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 878000,
    "disposalgroupincludingdiscontinuedoperationrevenue": 68000,
    "disposalgroupincludingdiscontinuedoperationgeneralandadministrativeexpense": 468000,
    "disposalgroupincludingdiscontinuedoperationoperatingincomeloss": -219000,
    "disposalgroupincludingdiscontinuedoperationinterestexpense": 87000,
    "discontinuedoperationgainlossfromdisposalofdiscontinuedoperationbeforeincometax": -306000,
    "discontinuedoperationprovisionforlossgainondisposalbeforeincometax": 6784000,
    "equitymethodinvestmentownershippercentage": 0.9,
    "investmentownedatcost": 4763102000,
    "amortizedcost": 11222000,
    "grossunrealizedgains": 53000,
    "grossunrealizedlosses": -4660000,
    "fairvalue": 11275000,
    "availableforsalesecuritiesdebtsecurities": 46439000,
    "investmentsfairvaluedisclosure": 16332000,
    "equitysecuritiesfvnicurrentandnoncurrent": 294000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassetvalue": 6905000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisearnings": 220000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassettransfersnet": 2000000,
    "fairvaluerecurringbasisunobservableinputreconciliationassetliabilitygainlossoci": -79000,
    "accountsreceivablegross": 247000,
    "accountsreceivablerelatedparty": 211000,
    "allowancefordoubtfulaccountsreceivable": 245000,
    "accountsreceivablenet": 213000,
    "stockoptionsexcludedfromantidiluted": 388409,
    "sharesissuableuponvestingofrestrictedstock": 684766,
    "stockissuedduringperiodsharesconversionofconvertiblesecurities": 1073175,
    "noncontrollinginterestinnetincomelossothernoncontrollinginterestsredeemable": -8354000,
    "netincomelossavailabletocommonstockholdersbasic": -1876000,
    "federalincometaxexpensebenefitcontinuingoperations": -6056000,
    "incomelossfromcontinuingoperationsbeforeincometaxesforeign": -2689000,
    "currentforeigntaxexpensebenefit": 19000,
    "currentstateandlocaltaxexpensebenefit": -274000,
    "currentincometaxexpensebenefit": -255000,
    "incometaxreconciliationtaxcontingencies": -255000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": 1877000,
    "incometaxreconciliationstateandlocalincometaxes": -479000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 2958000,
    "incometaxreconciliationforeignincometaxratedifferential": -583000,
    "saleofstatenols": -274000,
    "incometaxreconciliationtaxcredits": 255000,
    "deferredtaxassetsoperatinglosscarryforwards": 17852000,
    "deferredtaxassetsunrealizedlossesontradingsecurities": 30236000,
    "deferredtaxassetsdepreciation": -1000,
    "rdamortization": 689000,
    "deferredtaxassetstaxdeferredexpensereservesandaccruals": 237000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1858000,
    "deferredtaxassetsnet": 50871000,
    "deferredtaxassetsvaluationallowance": 50871000,
    "revenueremainingperformanceobligationpercentage": 0.53,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 388409,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 14.51,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 175000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 2.08,
    "weightedaverageremainingcontractualterminyearsgranted": "P9Y6M3D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexpirationsinperiod": 589205,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 218663,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm": "P8Y8M15D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 65456,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 20.98,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P8Y1M17D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.036,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P6Y1M9D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.95,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 684766,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestedweightedaveragegrantdatefairvalue": 4.04,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiod": 220019,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 1.99,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiod": 745867,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionvestedinperiodweightedaveragegrantdatefairvalue": 3.37,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeitedinperiod": 296759,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeituresweightedaveragegrantdatefairvalue": 5.1,
    "othergeneralandadministrativeexpense": 3044000,
    "otherresearchanddevelopmentexpense": 194000,
    "forfeitureofrsuswithingeneralandadministrative": -931000,
    "forfeitureofrsuswithinresearchanddevelopment": -119000,
    "allocatedsharebasedcompensationexpense": 2188000,
    "operatingleasesfutureminimumpaymentsdueinfouryears": 77000,
    "operatingleasesfutureminimumpaymentsdueinfiveyears": 78000,
    "operatingleasesfutureminimumpaymentsdue": 155000,
    "potentialownershippurchase": 0.95,
    "ownershipinterestinsubsidiaries": 0.5,
    "debtinstrumentinterestratestatedpercentage": 0.45,
    "saleofstockpercentageofownershipbeforetransaction": 0.51,
    "assetsheldforsalenotpartofdisposalgroupcurrentother": 57700000,
    "concentrationriskpercentage1": 0.42,
    "effectiveincometaxratecontinuingoperations": 0.5,
    "proceedsfromsaleofpropertyheldforsale": 49400000,
    "othernotespayable": 15000000,
    "proceedsfromrepaymentsofnotespayable": 33000000,
    "carryingcostspropertyandexplorationrights": 40200000,
    "otherrestructuringcosts": 1200000,
    "deferredrentreceivablesnet": 1200000,
    "indirectinterestassetspercentage": 0.45,
    "holdshareamount": 44000000,
    "minorityinterestownershippercentagebyparent": 0.56,
    "warrantexercisepriceincrease": 1.25,
    "purchaseofexercisewarrantshares": 16700000,
    "percentageofoutstandingcapitalstock": 0.51,
    "percentageofoutstandingcapitalstockonfullydilutedbasis": 0.42,
    "preferredstockparorstatedvaluepershare": 1.25,
    "percentageofconsolidationlessthanwhollyownedsubsidiaryparentownershipinterestchangespurchaseofinterestbyparent": 0.5,
    "fullydiluted": 0.1,
    "ownershipinterestpercentage": 0.51,
    "businesscombinationstepacquisitionequityinterestinacquireepercentage": 0.43,
    "financeleaseimpairmentloss": 17300000,
    "otherminorityinterests": 79100000,
    "interestamount": 10400000,
    "relatedpartytransactionrate": 0.11,
    "interestbearingliabilitiesaverageratepaid": 0.14,
    "promissorynoteinterestrate1": 0.18,
    "fairvalueadjustmentofwarrants": 79000,
    "interestincomeinterestearningasset": 54000,
    "lineofcreditfacilityinterestratedescription": "The Company owns 37.5% of the equity interestsin RP Finance and is required to fund 37.5% of funding requests from Cornerstone Pharmaceuticals under the RPF Line of Credit. The Instrumentowns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Cornerstone Pharmaceuticals underthe RPF Line of Credit. The remaining 25% equity interests in RP Finance are owned by other stockholders of Cornerstone Pharmaceuticals.",
    "percentageofissuedandoutstandingshares": 0.12,
    "lineofcreditfacilityinterestrateduringperiod": 0.375,
    "cumulativefundsdescription": "the Companyhas funded a cumulative total of $9.375 million in accordance with its 37.5% ownership interests in RP Finance.",
    "issuedandoutstandingordinarysharespercentage": 0.95,
    "investmentmaturitydate": "2021-09-01",
    "investmentownedbalanceshares": 15975000,
    "amountofaggregatepurchaseprice": 3000000,
    "cashpayment": 2600000,
    "investmentownedpercentofnetassets": 0.84,
    "redeemablenoncontrollinginterestequityothercarryingamount": 8000,
    "purchaseagreementdescription": "The Company purchased from Cyclo (i) 2,514,970 common shares (the “Purchased Shares”) and (ii) a warrant to purchase 2,514,970common shares with an exercise price of $0.71 per share (the “Cyclo Warrant”), at a combined purchase price equal to $0.835per Purchased Share and Cyclo Warrant to purchase one share, for an aggregate purchase price of $2.1 million.",
    "saleofstockpricepershare": 1.75,
    "unrealizedgainofpurchaseprice": 2100000,
    "totalaggregatefairvalue": 4763102000,
    "additionalcollateralaggregatefairvalue": 3898204000,
    "debtsecuritiesavailableforsaleaccumulatedgrossunrealizedgainlossbeforetax": 154000,
    "investmentownedatfairvalue": 100000,
    "equitysecuritiesfvnirealizedgainloss": 334000,
    "depreciation": 78000,
    "debtinstrumentmaturitydate": "2022-11-01",
    "interestexpensedebt": 87000,
    "costsandexpensesrelatedparty": 313000,
    "relatedpartytaxexpenseduetoaffiliatescurrent": 70000,
    "areaofland": 80000,
    "discontinuedoperationtaxeffectofdiscontinuedoperation": 211000,
    "cashincludingdiscontinuedoperations": 19000,
    "rentandparkingexpenses": 210000,
    "allowancefordoubtfulotherreceivablescurrent": 720000,
    "paymentsforleasingcosts": 10000,
    "revenuepercentage": 0.42,
    "relatedpartytransactionamountsoftransaction": 1600000,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 63200000,
    "stateandlocalincometaxexpensebenefitcontinuingoperations": 40400000,
    "foreignincometaxexpensebenefitcontinuingoperations": 7600000,
    "effectiveincometaxratereconciliationprioryearincometaxes": 0.8,
    "retainedearningsappropriated": 274000,
    "numberofoperatingsegments": 2,
    "stockrepurchaseprogramauthorizedamount1": 5000000,
    "restrictedstockunitsdescription": "On August 24, 2021, the Company issued 2,833,425 shares of Class B common stock (the “InstitutionalShares”), par value $0.01 per share, to the Institutional Investors, at a purchase price equal to $35.00 per share, for aggregategross proceeds of approximately $99.2 million, before deducting placement agent fees and other offering expenses.",
    "aggregategrossproceeds": 5000000,
    "proceedsfromissuanceorsaleofequity": 98000000,
    "deductingtransactioncosts": 6200000,
    "commonstockcapitalsharesreservedforfutureissuance": 953516,
    "conversionofstocksharesissued1": 2615795,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedstockoptions": 5000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P1Y5M8D",
    "sellingexpense": 307913000,
    "stockissuedduringperiodvaluesharebasedcompensationforfeited": 915000,
    "proceedsfromissuanceofwarrants": 8200000,
    "aggregatesharesofcommonstock": 218245,
    "saleofstockconsiderationreceivedpertransaction": 5000000,
    "warrantexercisepricedecrease": 22.91,
    "leaseexpirationdates": "The Company is the lessor of the Israeli propertywhich is leased to tenants under net operating leases with a term expiration date within 2025.",
    "comprehensiveincomelossnetoftaxattributabletononcontrollinginterests": 300000,
    "relatedpartiesterminateleasesdescription": "A related party has the right to terminate theIsraeli lease upon four months’ notice.",
    "depositassets": 825000,
    "entityregistrantname": "RAFAEL HOLDINGS, INC.",
    "tradingsymbol": "RFL",
    "documenttype": "10-K",
    "currentfiscalyearenddate": "--07-31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1713863,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2023-07-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "false",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityfilenumber": "000-55863",
    "entityincorporationstatecountrycode": "DE",
    "entitytaxidentificationnumber": "82-2296593",
    "entityaddressaddressline1": "520 Broad Street",
    "entityaddresscityortown": "Newark",
    "entityaddressstateorprovince": "NJ",
    "entityaddresspostalzipcode": 7102,
    "cityareacode": "(212)",
    "localphonenumber": "658-1450",
    "security12btitle": "Class B common stock, par value $0.01 per share",
    "securityexchangename": "NYSE",
    "entityinteractivedatacurrent": "Yes",
    "documentfinstmterrorcorrectionflag": "false",
    "auditorfirmid": 596,
    "auditorname": "CohnReznick LLP",
    "auditorlocation": "New York, New York"
  },
  {
    "date": "2022-07-30",
    "symbol": "RFL",
    "period": "FY",
    "cashequivalentsatcarryingvalue": 26537000,
    "availableforsalesecuritiesdebtsecuritiescurrent": 36698000,
    "accountsandotherreceivablesnetcurrent": 140000,
    "receivablesnetcurrent": 157000,
    "prepaidexpenseandotherassetscurrent": 4621000,
    "assetsheldforsalenotpartofdisposalgroupcurrent": 40194000,
    "assetscurrent": 108347000,
    "propertyplantandequipmentnet": 1770000,
    "investmentsotherpharmaceuticals": 477000,
    "investmentshedgefunds": 4764000,
    "inprocessresearchanddevelopment": 1575000,
    "otherassetsnoncurrent": 1387000,
    "assets": 118320000,
    "accountspayablecurrent": 564000,
    "accruedliabilitiescurrent": 1875000,
    "otherliabilitiescurrent": 3518000,
    "duetorelatedpartiescurrent": 69000,
    "notespayablecurrent": 15000000,
    "liabilitiescurrent": 21026000,
    "otherliabilitiesnoncurrent": 88000,
    "liabilities": 21114000,
    "commonstockvalue": 8000,
    "commonstockvalue1": 237000,
    "additionalpaidincapital": 262023000,
    "retainedearningsaccumulateddeficit": -165457000,
    "accumulatedothercomprehensiveincomelossavailableforsalesecuritiesadjustmentnetoftax": -63000,
    "accumulatedothercomprehensiveincomelossforeigncurrencytranslationadjustmentnetoftax": 3767000,
    "stockholdersequity": 100515000,
    "minorityinterest": -3309000,
    "stockholdersequityincludingportionattributabletononcontrollinginterest": -3309000,
    "liabilitiesandstockholdersequity": 118320000,
    "allowancefordoubtfulaccountsreceivablecurrent": 197000,
    "accountsreceivablerelatedpartiescurrent": 720000,
    "accountsreceivablerelatedpartiescurrentone": 9375000,
    "commonstockparorstatedvaluepershare": 0.01,
    "commonstocksharesauthorized": 200000000,
    "commonstocksharesissued": 23712449,
    "commonstocksharesoutstanding": 23687964,
    "operatingleasesincomestatementleaserevenue": 179000,
    "revenuefromrelatedparties": 111000,
    "revenuesotherrelatedparty": 120000,
    "revenues": 410000,
    "sellinggeneralandadministrativeexpense": 16978000,
    "researchanddevelopmentexpense": 8742000,
    "depreciationandamortization": 72000,
    "provisionforlossonreceivablepursuanttolineofcredit": 25000000,
    "provisionforlossesonrelatedpartyreceivables": 10095000,
    "operatingincomeloss": 181000,
    "interestexpense": 6000,
    "interestincomeother": 201000,
    "impairmentofcostmethodinvestmentrafaelpharmaceuticals": 79141000,
    "marketablesecuritiesunrealizedgainloss": -45000,
    "unrealizedgainoninvestmentshedgefund": 504000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": 181000,
    "incomelossfromequitymethodinvestments": -575000,
    "netincomeloss": -140547000,
    "discontinuedoperationgainlossondisposalofdiscontinuedoperationnetoftax": -1830000,
    "incomelossfromdiscontinuedoperationsnetoftax": -1830000,
    "profitloss": -17719000,
    "netincomelossattributabletononcontrollinginterest": -17719000,
    "netincomelossavailabletocommonstockholdersbasic": -124658000,
    "marketablesecuritiesunrealizedgainlossexcludingotherthantemporaryimpairments": -63000,
    "othercomprehensiveincomelossforeigncurrencytranslationadjustmenttax": 5000,
    "othercomprehensiveincomelossbeforereclassificationsnetoftax": -142445000,
    "comprehensivelossattributabletononcontrollinginterests": -17746000,
    "comprehensiveincomenetoftax": -124699000,
    "incomelossfromcontinuingoperationsincludingportionattributabletononcontrollinginterest": -140547000,
    "incomelossfromcontinuingoperationsattributabletononcontrollingentity": -17719000,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -122828000,
    "discontinuedoperationincomelossfromdiscontinuedoperationbeforeincometax": -1830000,
    "incomelossfromcontinuingoperationsperbasicshare": -6.22,
    "incomelossfromdiscontinuedoperationsnetoftaxperbasicshare": -0.09,
    "earningspersharebasic": -6.31,
    "weightedaveragenumberofsharesoutstandingbasic": 19767342,
    "incomelossfromcontinuingoperationsperdilutedshare": -6.22,
    "incomelossfromdiscontinuedoperationsnetoftaxperdilutedshare": -0.09,
    "earningspersharediluted": -6.31,
    "weightedaveragenumberofdilutedsharesoutstanding": 19767342,
    "sharesoutstanding": 23687964,
    "stockissuedduringperiodvaluesharebasedcompensation": 18061000,
    "stockissuedduringperiodsharessharebasedcompensation": 1533311,
    "stockissuedduringperiodvaluerestrictedstockawardforfeitures": 18978000,
    "stockissuedduringperiodsharessharebasedcompensationforfeited": -943305,
    "stockissuedduringperiodvaluenewissues": 99170000,
    "stockissuedduringperiodsharesnewissues": 2833425,
    "stockissuedduringperiodvalueother": -6228000,
    "stockissuedduringperiodvalueacquisitions": -8000,
    "stockissuedduringperiodvalueissuedforservices": 10997000,
    "stockissuedduringperiodsharesissuedforservices": 237761,
    "stockissuedduringperiodvalueemployeestockpurchaseplan": 75000,
    "shareswithheldforpayrolltaxesinshares": -10638,
    "othercomprehensiveincomeunrealizedholdinggainlossonsecuritiesarisingduringperiodnetoftax": -63000,
    "foreigncurrencytransactiongainlossbeforetax": -5000,
    "incomelossfromdiscontinuedoperationsnetoftaxattributabletoreportingentity": 1830000,
    "incomelossfromcontinuingoperations": -140547000,
    "depreciationdepletionandamortization": 72000,
    "gainlossoninvestmentshedgefund": -504000,
    "debtsecuritiesavailableforsalerealizedgainloss": -45000,
    "provisionfordoubtfulaccounts": 4000,
    "sharebasedcompensation": -917000,
    "increasedecreaseinotherreceivables": 140000,
    "increasedecreaseinaccountsandotherreceivables": -74000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 3545000,
    "increasedecreaseinotheroperatingassets": -130000,
    "increasedecreaseinaccountspayableandaccruedliabilities": 52000,
    "increasedecreaseinothercurrentliabilities": 3566000,
    "increasedecreaseinduetorelatedparties": -67000,
    "increasedecreaseinduefromrelatedparties": 120000,
    "increasedecreaseinduefromrafaelpharmaceuticals": 120000,
    "increasedecreaseinotheroperatingcapitalnet": -40000,
    "netcashprovidedbyusedinoperatingactivitiescontinuingoperations": -26038000,
    "cashprovidedbyusedinoperatingactivitiesdiscontinuedoperations": -41000,
    "netcashprovidedbyusedinoperatingactivities": -26079000,
    "purchasesdispositionsofpropertyandequipment": -2000,
    "paymenttofundrpfinancelineofcredit": 1875000,
    "paymenttorafaelpharmaceuticalspursuanttolineofcredit": 25000000,
    "paymentstoacquireavailableforsalesecuritiesdebt": 65306000,
    "proceedsfrommaturitiesprepaymentsandcallsofavailableforsalesecurities": 28500000,
    "netcashprovidedbyusedininvestingactivitiescontinuingoperations": -63683000,
    "cashprovidedbyusedininvestingactivitiesdiscontinuedoperations": -113000,
    "netcashprovidedbyusedininvestingactivities": -63796000,
    "proceedsfromissuanceofcommonstock": 99170000,
    "proceedsfromissuanceofcommonstockfromrelatedparty": 10997000,
    "proceedsfromissuanceofpreferredstockandpreferencestock": -6228000,
    "paymentsrelatedtotaxwithholdingforsharebasedcompensation": 75000,
    "netcashprovidedbyusedinfinancingactivitiescontinuingoperations": 103864000,
    "netcashprovidedbyusedinfinancingactivities": 103864000,
    "effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalents": -306000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 13683000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 26537000,
    "acquisitionofadditionalownershipinterestinlipomedix": 8000,
    "cashandcashequivalentsatcarryingvalue": 26537000,
    "totalcashandcashequivalentandrestrictedcashshowninstatementofcashflows": 26537000,
    "investmentinaltiratextblock": "NOTE 4 – INVESTMENT IN ALTIRA ",
    "investmentinrpfinancellctextblock": "NOTE 5 – INVESTMENT IN RP FINANCE, LLC ",
    "reclassificationpolicytextblock": "Reclassifications ",
    "liquiditypolicytextblock": "Liquidity ",
    "riskanduncertainties": "Risks and Uncertainties - COVID-19, War in Ukraine ",
    "allowancefordoubtfulaccountspolicytextblock": "Allowance for Doubtful Accounts  ",
    "investmentshedgefundspolicytextblock": "Investments - Hedge Funds ",
    "corporatebondspolicytextblock": "Corporate Bonds ",
    "assetsheldforsaleanddiscontinuedoperationspolicytextblock": "Assets Held-for-Sale and Discontinued Operations ",
    "debtissuancecostspolicytextblock": "Debt Issuance Costs ",
    "countryofincorporation": "United States – Delaware",
    "ownershipinterestinsubsidiary": 0.45,
    "propertyplantandequipmentusefullife": 5,
    "buildingsandimprovementsgross": 2505000,
    "land": 10412000,
    "furnitureandfixturesgross": 1145000,
    "assetsheldforsalenotpartofdisposalgroupother": 205000,
    "propertyplantandequipmentgross": 2573000,
    "propertysubjecttooravailableforoperatingleasenet": 17005000,
    "propertyplantandequipmentothernet": 40194000,
    "totalassetsheldforsale": 40194000,
    "costofrevenue": 3499000,
    "othersellinggeneralandadministrativeexpense": 2683000,
    "otherdepreciationandamortization": 1317000,
    "gainlossondispositionofrealestatediscontinuedoperations": -501000,
    "othergeneralexpense": 157000,
    "interestexpenseother": 1486000,
    "netincomelossfromdiscontinuedoperationsavailabletocommonshareholdersbasic": 1830000,
    "costofgoodsandservicessoldamortization": 36761000,
    "grossunrealizedgainsoninvestments": 81000,
    "grossunrealizedlossesoninvestments": 144000,
    "fairvalueinvestments": 36698000,
    "assetsdesignatedtoclosedblockequitysecuritiesavailableforsaleatfairvalue": 36698000,
    "hedgefunds": 4764000,
    "availableforsalesecuritiestotal": 41462000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassetvalue": 4764000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilityperiodincreasedecrease": -504000,
    "accountsreceivablegross": 196000,
    "accountsreceivablerelatedparties": 158000,
    "allowancefordoubtfulaccountsreceivable": 197000,
    "accountsreceivablenet": 157000,
    "propertyplantandequipmentother": 68000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 803000,
    "stockoptionsexcludedfromantidiluted": 1021277,
    "sharesissuableuponvestingofrestrictedstock": 1507373,
    "total": 2528650,
    "federalincometaxexpensebenefitcontinuingoperations": -137978000,
    "incomelossfromcontinuingoperationsbeforeincometaxesforeign": -1994000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": 29514000,
    "incometaxreconciliationstateandlocalincometaxes": 8752000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": -35001000,
    "incometaxreconciliationforeignincometaxratesdifferential": 459000,
    "incometaxreconciliationpermanentdifferences": -3632000,
    "incometaxreconciliationotheradjustments": -92000,
    "deferredtaxassetsoperatinglosscarryforwards": 15170000,
    "unrealizedgainlossonderivatives": 31850000,
    "depreciation": 1000,
    "deferredtaxassetstaxdeferredexpensereservesandaccruals": 236000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1839000,
    "deferredtaxassetsnet": 49096000,
    "deferredtaxassetsvaluationallowance": 49096000,
    "revenueremainingperformanceobligationpercentage": 0.07,
    "noncurrentassets": 1770000,
    "totalasset": 118320000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 5266,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsweightedaverageexerciseprice": 3.82,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm": 3.05,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 5266,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 3.12,
    "weightedaverageremainingcontractualterminyearsgranted": 9.76,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiod": 180441,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": 9.76,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 1316,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 3.82,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": 9.76,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.03,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 5.63,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.97,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 1507373,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestedweightedaveragegrantdatefairvalue": 4.22,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiod": 1533311,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 4.24,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiod": 90608,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionvestedinperiodweightedaveragegrantdatefairvalue": 16.86,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeitedinperiod": 943305,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeituresweightedaveragegrantdatefairvalue": 48.5,
    "generalandadministrativeexpense": 17270000,
    "otherresearchanddevelopmentexpense": 791000,
    "forfeitureofrsuswithingeneralandadministrative": -18978000,
    "operatingleasesfutureminimumpaymentsdueinthreeyears": 75000,
    "operatingleasesfutureminimumpaymentsdueinfouryears": 77000,
    "operatingleasesfutureminimumpaymentsdueinfiveyears": 78000,
    "operatingleasesfutureminimumpaymentsdue": 230000,
    "ownershipinterestinsubsidiaries": 0.9,
    "debtinstrumentinterestratestatedpercentage": 0.45,
    "outstandingcapitalstock": 0.51,
    "capitalstock": 0.41000000000000003,
    "othercashequivalentsatcarryingvalue": 26500000,
    "salesecurities": 36700000,
    "alternativeinvestment": 4800000,
    "concentrationsriskpercentage": 0.58,
    "provisionforotherlosses": 4000,
    "amortizationoffinancingcostsanddiscounts": 472000,
    "effectiveincometaxratecontinuingoperations": 0.5,
    "escrowdepositdisbursementsrelatedtopropertyacquisition1": 3250000,
    "othernotespayable": 15000000,
    "proceedsfromrepaymentsofnotespayable": 33000000,
    "prepaidexpensecurrentandnoncurrent": 150000,
    "otherassets": 1300000,
    "percentageofconsolidationlessthanwhollyownedsubsidiaryparentownershipinterestchangespurchaseofinterestbyparent": 0.9,
    "potentialownershippurchase": 0.5,
    "indirectinterestassetspercentage": 0.45,
    "fullydiluted": 0.1,
    "exercisepriceofwarrantsorrightsdescription": "Pharma Holdings holds 44.0 million shares of CornerstonePharmaceutical’s Series D Convertible Preferred Stock and a warrant to increase the combined ownership of Pharma Holdings and CS Pharmato up to 56% of the fully diluted equity interests in Cornerstone Pharmaceuticals (the “Warrant”). The exercise price of theWarrant is the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments. ",
    "purchaseofexercisewarrantshares": 16700000,
    "percentageofoutstandingcapitalstock": 0.51,
    "percentageofoutstandingcapitalstockonfullydilutedbasis": 0.41000000000000003,
    "financeleaseimpairmentloss": 17300000,
    "otherminorityinterests": 79100000,
    "interestamount": 6900000,
    "debtinstrumentinterestrateduringperiod": 0.09,
    "securitiespurchasedunderagreementstoresellallowanceforcreditlossrecovery": 25000000,
    "additionstootherassetsamount": 2600000,
    "interestincomeforeigndeposits": 1900000,
    "membershipinterestpercentage": 0.33333,
    "investments": 7000000,
    "businesscombinationcontingentconsiderationliabilitycurrent": 6000000,
    "lineofcreditfacilityinterestratedescription": "The Company owns 37.5% of the equity interestsin RP Finance and is required to fund 37.5% of funding requests from Cornerstone Pharmaceuticals under the RPF Line of Credit. HowardJonas owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Cornerstone Pharmaceuticalsunder the RPF Line of Credit. The remaining 25% equity interests in RP Finance are owned by other shareholders of Cornerstone Pharmaceuticals. ",
    "percentageofissuedandoutstandingshares": 0.12,
    "proceedsfrominterestreceived": 383000,
    "lineofcreditfacilityinterestrateduringperiod": 0.375,
    "cumulativefundsdescription": "As of July 31, 2022, the Company has fundeda cumulative total of $9.375 million in accordance with its 37.5% ownership interests in RP Finance.",
    "interestincomerelatedparty": 1900000,
    "relatedpartyreceivables": 9375000,
    "issuedandoutstandingordinarysharespercentage": 0.84,
    "sharesissued": 15975000,
    "amountofaggregatepurchaseprice": 3000000,
    "cashpayment": 2600000,
    "noncontrollinginterestpercentage": 0.16,
    "redeemablenoncontrollinginterestequityothercarryingamount": 8000,
    "othercomprehensiveincomelossreclassificationadjustmentfromaociforsaleofsecuritiesnetoftax": 45000,
    "otherinvestmentsandsecuritiesatcost": 500000,
    "debtinstrumentmaturitydate": "November 1, 2022",
    "interestexpensedebt": 1200000,
    "adjustmentforamortization": 472000,
    "relatedpartytransactionexpensesfromtransactionswithrelatedparty": 343000,
    "relatedpartytransactionduefromtorelatedparty": 69000,
    "areaofland": 3600,
    "rentandparkingexpenses": 157000,
    "duefromaffiliatecurrent": 720000,
    "notesreceivablerelatedpartiescurrent": 720000,
    "gainlossonfairvaluehedgesrecognizedinearnings": 575000,
    "equitymethodinvestmentownershippercentage": 0.375,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 54900000,
    "stateandlocalincometaxexpensebenefitcontinuingoperations": 35700000,
    "foreignincometaxexpensebenefitcontinuingoperations": 4900000,
    "effectiveincometaxratereconciliationprioryearincometaxes": 0.8,
    "numberofoperatingsegments": 2,
    "saleofbuildingdescription": "The Real Estate segment consists of the Company’sreal estate holdings, comprised of a portion of a commercial building in Israel. ",
    "losscontingencysettlementagreementterms": "As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installmentpayments through November 2021, which the Company has fully paid.",
    "issuanceofrestrictedshares": 5000000,
    "deductingtransactioncosts": 6200000,
    "conversionofstocksharesissued1": 10000,
    "stockissuedduringperiodsharesrestrictedstockawardgross": 1533311,
    "commonstockcapitalsharesreservedforfutureissuance": 4734,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedstockoptions": 4900000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": 3.25,
    "proceedsfromissuanceofwarrants": 8199999.999999999,
    "aggregatesharesofcommonstock": 218245,
    "saleofstockconsiderationreceivedpertransaction": 5000000,
    "classofwarrantorrightreasonforissuingtononemployees": "The warrants are exercisableat a per share exercise price of $22.91, and are exercisable at any time on or after December 7, 2020 through June 6, 2022.",
    "leaseexpirationdates": "The Company is the lessor of certain propertieswhich are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029.",
    "comprehensiveincomelossnetoftaxattributabletononcontrollinginterests": 300000,
    "amortizationofdeferredpropertytaxes": 212000,
    "relatedpartyleasesexpiredescription": "The Company has related party leases that expirein April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at520 Broad Street, Newark, New Jersey, and (ii) 3,595 square feet in Israel.",
    "leaseandrentalexpense": 2000000,
    "purchaserreceivecreditamount": 15000000,
    "subsequenteventeffectofchangeintaxstatus": 33000000,
    "entityregistrantname": "RAFAEL HOLDINGS, INC.",
    "tradingsymbol": "RFL",
    "documenttype": "10-K",
    "currentfiscalyearenddate": "--07-31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1713863,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "July 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityfilenumber": "000-55863",
    "entityincorporationstatecountrycode": "Delaware",
    "entitytaxidentificationnumber": "82-2296593",
    "entityaddressaddressline1": "520 Broad Street",
    "entityaddresscityortown": "Newark",
    "entityaddressstateorprovince": "New Jersey",
    "entityaddresspostalzipcode": 7102,
    "cityareacode": "(212)",
    "localphonenumber": "658-1450",
    "security12btitle": "Class B common stock, par value $0.01 per share",
    "securityexchangename": "New York Stock Exchange",
    "entityinteractivedatacurrent": "Yes",
    "auditorfirmid": 596,
    "auditorname": "CohnReznick LLP",
    "auditorlocation": "New York, New York"
  },
  {
    "date": "2021-07-30",
    "symbol": "RFL",
    "period": "FY",
    "cashequivalentsatcarryingvalue": 7854000,
    "restrictedcashcurrent": 5000000,
    "receivablesnetcurrent": 235000,
    "duefromrafaelpharmaceuticals": 600000,
    "prepaidexpenseandotherassetscurrent": 111000,
    "assetscurrent": 14764000,
    "propertyplantandequipmentnet": 43238000,
    "equityinvestmentrpfinance": 575000,
    "duefromrelatedpartiesnoncurrent": 7500000,
    "longterminvestments": 79141000,
    "investmentsotherpharmaceuticals": 477000,
    "investmentshedgefunds": 5268000,
    "inprocessresearchanddevelopment": 1575000,
    "otherassetsnoncurrent": 1517000,
    "assets": 154055000,
    "accountspayablecurrent": 1160000,
    "accruedliabilitiescurrent": 1227000,
    "duetorelatedpartiescurrent": 136000,
    "notespayablecurrent": 14528000,
    "otherliabilitiescurrent": 252000,
    "liabilitiescurrent": 17303000,
    "otherliabilitiesnoncurrent": 48000,
    "liabilities": 17351000,
    "commonstockvalue": 8000,
    "commonstockvalue1": 169000,
    "additionalpaidincapital": 159136000,
    "retainedearningsaccumulateddeficit": -40799000,
    "accumulatedothercomprehensiveincomelossnetoftax": 3772000,
    "stockholdersequity": 122286000,
    "minorityinterest": 14418000,
    "stockholdersequityincludingportionattributabletononcontrollinginterest": 14418000,
    "liabilitiesandstockholdersequity": 154055000,
    "allowancefordoubtfulaccountsreceivablecurrent": 193000,
    "commonstockparorstatedvaluepershare": 0.01,
    "commonstocksharesauthorized": 200000000,
    "commonstocksharesissued": 16947066,
    "commonstocksharesoutstanding": 16936864,
    "operatingleasesincomestatementleaserevenue": 890000,
    "revenuefromrelatedparties": 2099000,
    "parkingrevenues": 502000,
    "revenuesotherrelatedparty": 480000,
    "revenues": 3971000,
    "sellinggeneralandadministrativeexpense": 20416000,
    "researchanddevelopmentexpense": 4907000,
    "depreciationandamortization": 1460000,
    "goodwillimpairmentloss": 7000000,
    "operatingincomeloss": -29812000,
    "interestincomeexpensenet": -102000,
    "marketablesecuritiesgainloss": 749000,
    "impairmentofinvestments": 724000,
    "unrealizedgainoninvestmentshedgefund": -4758000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -25131000,
    "incometaxexpensebenefit": 18000,
    "incomelossfromequitymethodinvestments": 383000,
    "netincomeloss": -222000,
    "incomelossfromcontinuingoperationsattributabletononcontrollingentity": -222000,
    "comprehensiveincomenetoftaxattributabletononcontrollinginterest": 24544000,
    "consolidatednetloss": -24766000,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": 10000,
    "othercomprehensiveincomelossnetoftax": -24756000,
    "othercomprehensiveincomelosstaxportionattributabletononcontrollinginterest": -37000,
    "comprehensiveincomenetoftax": -24793000,
    "earningspersharebasicanddiluted": -1.49,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 16522686,
    "sharesoutstanding": 16936864,
    "allocatedsharebasedcompensationexpense": 6347000,
    "stockissuedduringperiodsharessharebasedcompensation": 953329,
    "stockissueduringperiodvaluestockbasedcompensationtoboardofdirectors": 286000,
    "stockbasedcompensationtoboardofdirectorsshares": 12609,
    "stockissuedduringperiodvaluenewissues": 2000000,
    "stockissuedduringperiodsharesnewissues": 280323,
    "stockissuedduringperiodvaluepurchaseofassets": 13000000,
    "stockissuedduringperiodsharespurchaseofassets": 567437,
    "stockissuedduringperiodvalueother": -185000,
    "shareswithheldforpayrolltaxes": -7214,
    "adjustmentstoadditionalpaidincapitalwarrantissued": 2000000,
    "stockissuedduringperiodsharesother": 87298,
    "stockissuedduringperiodvaluestockoptionsexercised": 71000,
    "stockissuedduringperiodsharesstockoptionsexercised": 14546,
    "capitalcontributionfornoncontrollinginterest": 912000,
    "foreigncurrencytranslationadjustment": 10000,
    "depreciationdepletionandamortization": 1460000,
    "deferredincometaxesandtaxcredits": 6000,
    "gainlossoninvestmentshedgefund": 4758000,
    "assetimpairmentcharges": 7000000,
    "provisionfordoubtfulaccounts": 193000,
    "sharebasedcompensation": 6633000,
    "amortizationoffinancingcosts": 28000,
    "gainlossonsaleofproperties": 749000,
    "increasedecreaseinaccountsreceivable": 161000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 802000,
    "increasedecreaseinotheroperatingassets": -63000,
    "increasedecreaseinaccountspayableandaccruedliabilities": 164000,
    "increasedecreaseinothercurrentliabilities": 137000,
    "increasedecreaseinduetorelatedparties": 136000,
    "increasedecreaseinduefromrelatedparties": 482000,
    "increasedecreaseinotherliabilities": -44000,
    "netcashprovidedbyusedinoperatingactivities": -15601000,
    "paymentstoacquirepropertyplantandequipment": 206000,
    "proceedsfromsaleofpropertyplantandequipment": 3658000,
    "proceedsfromsaleandmaturityofmarketablesecurities": 7000000,
    "paymentstoacquireavailableforsalesecuritiesequity": 7500000,
    "investmentinaltira": 2000000,
    "paymentstoacquirelongterminvestments": 9123000,
    "netcashprovidedbyusedininvestingactivities": -8171000,
    "proceedsfromminorityshareholders": 912000,
    "proceedsfromissuanceofcommonstock": 2000000,
    "proceedsfromstockoptionsexercised": 71000,
    "paymentsrelatedtotaxwithholdingforsharebasedcompensation": 185000,
    "proceedsfromwarrantexercises": 2000000,
    "proceedsfromnotespayable": 15000000,
    "paymentsofdebtissuancecosts": 500000,
    "netcashprovidedbyusedinfinancingactivities": 30298000,
    "effectofexchangerateoncashandcashequivalents": 122000,
    "cashandcashequivalentsperiodincreasedecrease": 6648000,
    "cashandcashequivalentsatcarryingvalue": 12854000,
    "commonsharesissuedforpaymentofpurchasepriceforaltiraequity": 8501000,
    "cashandcashequivalents": 7854000,
    "restrictedcash1": 5000000,
    "totalcashcashequivalentsandrestrictedcashshowninstatementofcashflows": 12854000,
    "investmentinaltiratextblock": "NOTE3 – INVESTMENT IN ALTIRA ",
    "investmentinrpfinancellctextblock": "NOTE4 – INVESTMENT IN RP FINANCE, LLC ",
    "liquiditypolicytextblock": "Liquidity ",
    "riskanduncertainties": "Risksand Uncertainties - COVID-19 ",
    "propertiespolicytextblock": "Properties ",
    "scheduleofstraightlinebasisovertheirestimatedusefullivestabletextblock": "       Classification     Years       Building and improvements      40       Tenant improvements      7-15       Other (primarily equipment and furniture and fixtures)      5    ",
    "countryofincorporation": "United States – Delaware",
    "ownershipinterestinsubsidiary": 0.45,
    "propertyplantandequipmentestimatedusefullives": 5,
    "hedgefunds": 5268000,
    "availableforsalesecurities": 5268000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassetvalue": 5268000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassettransfersnet": -7000000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassetgainlossincludedinearnings1": 4758000,
    "accountsreceivablegross": 315000,
    "accountsreceivablerelatedpartiescurrent": 113000,
    "allowancefordoubtfulaccountsreceivable": 193000,
    "accountsreceivablenet": 235000,
    "buildingsandimprovementsgross": 47841000,
    "land": 10412000,
    "furnitureandfixturesgross": 1145000,
    "propertyplantandequipmentother": 271000,
    "propertyplantandequipmentgross": 59669000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 16431000,
    "federalincometaxexpensebenefitcontinuingoperations": -24251000,
    "incomelossfromcontinuingoperationsbeforeincometaxesforeign": -880000,
    "incomelossfromcontinuingoperationsbeforeincometaxesminorityinterestandincomelossfromequitymethodinvestments": -25131000,
    "currentforeigntaxexpensebenefit": -19000,
    "currentstateandlocaltaxexpensebenefit": 1000,
    "currentincometaxexpensebenefit": -18000,
    "provisionforincometaxes": -18000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": 5278000,
    "incometaxreconciliationstateandlocalincometaxes": 1724000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": -7039000,
    "incometaxreconciliationforeignincometaxratesdifferential": 203000,
    "incometaxreconciliationotheradjustments": -184000,
    "incometaxreconciliationtaxcontingencies": 18000,
    "deferredtaxassetsoperatinglosscarryforwards": 12495000,
    "unrealizedgainlossonderivatives": 968000,
    "depreciation": 2583000,
    "deferredtaxassetstaxdeferredexpensereservesandaccrualsreturnsandallowances": 54000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 2096000,
    "deferredtaxassetsnet": 18196000,
    "deferredtaxassetsvaluationallowance": 18196000,
    "operatingleasesfutureminimumpaymentsdueintwoyears": 2860000,
    "operatingleasesfutureminimumpaymentsdueinthreeyears": 2709000,
    "operatingleasesfutureminimumpaymentsdueinfouryears": 2693000,
    "operatingleasesfutureminimumpaymentsdueinfiveyears": 2209000,
    "operatingleasesfutureminimumpaymentsduethereafter": 1948000,
    "operatingleasesfutureminimumpaymentsdue": 12419000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiod": 118409,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 40.85,
    "stockissuedduringperiodsharestocksoptionsexercised": -14546,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiod": 1323,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardofoptionsoutstandingendingbalance": 683414,
    "weightedaverageexercisepriceoutstandingendingbalance": 11.13,
    "weightedaverageremainingcontractualtermoutstandingendingbalance": 3.05,
    "aggregateintrinsicvalueoutstandingendingbalance": 26982000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 565005,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": 1.65,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 25826000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.01,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 6.04,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.75,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 1007975,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestedweightedaveragegrantdatefairvalue": 46.77,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiod": 956317,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 48.34,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiod": 69347,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionvestedinperiodweightedaveragegrantdatefairvalue": 10.76,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeitedinperiod": 2099,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeituresweightedaveragegrantdatefairvalue": 13.54,
    "operatingincomeloss1": -29812000,
    "revenueremainingperformanceobligationpercentage": 0.07,
    "noncurrentassets": 43238000,
    "totalasset": 154055000,
    "stockoptionsexcludedfromantidiluted": 683414,
    "sharesissuableuponexerciseofwarrants": 26189,
    "dilutivelosspershareindollars": 709603,
    "ownershipinterestinsubsidiaries": 0.9,
    "debtinstrumentinterestratestatedpercentage": 0.45,
    "paymentsforproceedsfromhedgeinvestingactivities": 5300000,
    "longtermdebtterm": "three months",
    "concentrationsriskpercentage1": 0.65,
    "numberofcustomers": 2,
    "provisionforotherlosses": 193000,
    "amortizationoffinancingcostsanddiscounts": 27776,
    "effectiveincometaxratecontinuingoperations": 0.5,
    "percentageofconsolidationlessthanwhollyownedsubsidiaryparentownershipinterestchangespurchaseofinterestbyparent": 0.9,
    "potentialownershippurchase": 0.5,
    "indirectinterestassetspercentage": 0.45,
    "fullydiluted": 0.1,
    "exercisepriceofwarrantsorrightsdescription": "PharmaHoldings holds 44.0 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownershipto up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisableat the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments. ",
    "percentageofoutstandingcapitalstock": 0.51,
    "percentageofoutstandingcapitalstockonfullydilutedbasis": 0.41000000000000003,
    "sharesissued": 2021802,
    "membershipinterestpercentage": 0.33333,
    "investments": 7000000,
    "businesscombinationcontingentconsiderationliabilitycurrent": 6000000,
    "equitymethodinvestments": 7000000,
    "saleofstocknumberofsharesissuedintransaction": 43649,
    "saleofstockconsiderationreceivedontransaction": 5000000,
    "othercommitment": 10000000,
    "lineofcreditfacilityinterestratedescription": "TheCompany owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Rafael Pharmaceuticalsunder the Line of Credit Agreement. Howard Jonas owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of fundingrequests from Rafael Pharmaceuticals under the Line of Credit Agreement. The remaining 25% equity interests in RP Finance is owned byother shareholders of Rafael Pharmaceuticals. ",
    "percentageofissuedandoutstandingshares": 0.12,
    "proceedsfrominterestreceived": 383000,
    "lineofcreditfacilityinterestrateduringperiod": 0.375,
    "ownershipamount": 7500000,
    "issuedandoutstandingordinarysharespercentage": 0.68,
    "debtinstrumentfaceamount": 400000,
    "financinginterestexpense": 10290,
    "debtinstrumentinterestrateincreasedecrease": 0.15,
    "otherinvestmentsandsecuritiesatcost": 500000,
    "operatingleaseimpairmentloss": 700000,
    "deferredcostsandotherassets": 1500000,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 47000000,
    "stateandlocalincometaxexpensebenefitcontinuingoperations": 27800000,
    "foreignincometaxexpensebenefitcontinuingoperations": 2900000,
    "effectiveincometaxratereconciliationprioryearincometaxes": 0.8,
    "interestexpensedebt": 64315,
    "debtinstrumentunamortizeddiscountpremiumanddebtissuancecostsnet": 472184,
    "adjustmentforamortization": 27776,
    "leaseexpirationdates": "The Company is the lessor of certain propertieswhich are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029.",
    "comprehensiveincomelossnetoftaxattributabletononcontrollinginterests": 3000000,
    "relatedpartyleasesexpiredescription": "The Company has related party leases that expirein April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at520 Broad Street, Newark, New Jersey, and (ii) 3,595 square feet in Israel.",
    "leaseandrentalexpense": 2000000,
    "losscontingencysettlementagreementterms": "As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installmentpayments through November 2021,",
    "legalfees": 32000,
    "relatedpartytransactionexpensesfromtransactionswithrelatedparty": 322000,
    "relatedpartytransactionduefromtorelatedparty": 136000,
    "areaofland": 3600,
    "rentandparkingexpenses": 1800000,
    "duefromaffiliates": 168000,
    "costsandexpensesrelatedparty": 480000,
    "duefromaffiliatecurrent": 600,
    "relatedpartytransactiondescriptionoftransaction": "The Company leases space to related parties whichrepresented approximately 65% and 52% of the Company’s total revenue for the years ended July 31, 2021 and 2020, respectively.See Note 11 for future minimum rent payments from related parties and other tenants. ",
    "customerfunds": 657000,
    "subsidiaryorequitymethodinvesteeownershippercentagedescription": "For the years ended July 31, 2021 and 2020,respectively, the Company recognized approximately $383 thousand and $192 thousand in income from its ownership interests of 37.5% inRP Finance, respectively. ",
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 22.91,
    "issuanceofrestrictedshares": 2090954,
    "issuanceofavailableshares": 83484,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 118409,
    "stockbasedcompensationexpense": 500000,
    "vestingextendingdescription": "These options are subject to graded vesting extending through April 15, 2025.",
    "optionswereexercised": 14546,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedstockoptions": 41500000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": 9.09,
    "serviceterm": "three years",
    "expenseforsharesvested": 45100000,
    "restrictedstockunitsdescription": "the Company grantedemployees and consultants 47,820 and 24,071 restricted shares of Class B Common Stock, respectively, which will vest over approximatelythree years. The aggregate fair value of the grants in fiscal 2021 and 2020 was approximately $1.1 million and $478 thousand, respectively,which is being charged to expense on a straight-line basis as the shares vest.",
    "totalgrantdatefairvalue": 746000,
    "proceedsfromissuanceofwarrants": 8199999.999999999,
    "aggregatesharesofcommonstock": 218245,
    "saleofstockconsiderationreceivedpertransaction": 5000000,
    "purchaseofwarrantsgrantedpercentage": -0.2,
    "classofwarrantorrightnumberofsecuritiescalledbywarrantsorrights": 113487,
    "classofwarrantorrightreasonforissuingtononemployees": "The warrants are exercisable at a pershare exercise price of $22.91, and are exercisable at any time on or after December 7, 2020 through June 6, 2022.",
    "stockissuedduringperiodvaluestockwarrantexercised": 87298,
    "classofwarrantorrightoutstanding": 26189,
    "commonstockanexercisedate": "June 6, 2022",
    "numberofreportablesegments": 2,
    "descriptionofpurchaseagreementperiodicpayments": "In September 2021, Rafael Pharmaceuticals called for a $5 million drawon the line of credit facility and the Company has funded an additional $1.875 million in accordance with its 37.5% ownership interestsin RP Finance.",
    "entityregistrantname": "RAFAELHOLDINGS, INC.",
    "tradingsymbol": "RFL",
    "documenttype": "10-K",
    "currentfiscalyearenddate": "July 31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1713863,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "July 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "No",
    "entityextransitionperiod": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityfilenumber": "000-55863",
    "entityincorporationstatecountrycode": "Delaware",
    "entitytaxidentificationnumber": "82-2296593",
    "entityaddressaddressline1": "520Broad Street",
    "entityaddresscityortown": "Newark",
    "entityaddressstateorprovince": "New Jersey",
    "entityaddresspostalzipcode": 7102,
    "cityareacode": "(212)",
    "localphonenumber": "658-1450",
    "security12btitle": "Class B common stock, par value $0.01 per share",
    "securityexchangename": "NewYork Stock Exchange",
    "entityinteractivedatacurrent": "Yes"
  },
  {
    "date": "2020-07-30",
    "symbol": "RFL",
    "period": "FY",
    "cashandcashequivalentsatcarryingvalue": 6206000,
    "receivablesnetcurrent": 267000,
    "duefromrafaelpharmaceuticals": 118000,
    "prepaidexpenseandotherassetscurrent": 11000,
    "assetsheldforsalecurrent": 2968000,
    "assetscurrent": 9832000,
    "propertyplantandequipmentnet": 44433000,
    "equityinvestmentrpfinance": 192000,
    "longterminvestments": 70018000,
    "investmentsotherpharmaceuticals": 1201000,
    "investmentshedgefunds": 7510000,
    "deferredincometaxassetsnet": 6000,
    "inprocessresearchanddevelopment": 1575000,
    "otherassetsnoncurrent": 1500000,
    "assets": 136347000,
    "accountspayablecurrent": 921000,
    "accruedliabilitiescurrent": 1191000,
    "duetorelatedpartiescurrent": 3500000,
    "otherliabilitiescurrent": 115000,
    "liabilitiescurrent": 5727000,
    "otherliabilitiesnoncurrent": 92000,
    "liabilities": 5819000,
    "commonstockvalue": 149000,
    "additionalpaidincapital": 129136000,
    "retainedearningsaccumulateddeficit": -16255000,
    "accumulatedothercomprehensiveincomelossnetoftax": 3762000,
    "stockholdersequity": 116800000,
    "minorityinterest": 13728000,
    "stockholdersequityincludingportionattributabletononcontrollinginterest": 13728000,
    "liabilitiesandstockholdersequity": 136347000,
    "allowancefordoubtfulaccountsreceivablecurrent": 218000,
    "commonstockparorstatedvaluepershare": 0.01,
    "commonstocksharesauthorized": 200000000,
    "commonstocksharesissued": 15034598,
    "commonstocksharesoutstanding": 15028536,
    "operatingleasesincomestatementleaserevenue": 1516000,
    "revenuefromrelatedparties": 2082000,
    "parkingrevenues": 832000,
    "revenuesotherrelatedparty": 480000,
    "revenues": 4910000,
    "sellinggeneralandadministrativeexpense": 9118000,
    "researchanddevelopmentexpense": 2391000,
    "depreciationandamortization": 1866000,
    "operatingincomeloss": -8465000,
    "interestincomeexpensenet": -32000,
    "foreigncurrencytransactiongainlossbeforetax": -5000,
    "impairmentofinvestments": 4000000,
    "unrealizedgainoninvestmentshedgefund": -2385000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -6916000,
    "incometaxexpensebenefit": 29000,
    "impairmentofequitymethodinvestmentofaltira": 4000000,
    "incomelossfromequitymethodinvestments": 192000,
    "profitloss": -338000,
    "netincomelossattributabletononcontrollinginterest": -338000,
    "netincomeloss": -10415000,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": -22000,
    "comprehensiveincomenetoftaxincludingportionattributabletononcontrollinginterest": -10775000,
    "comprehensiveincomenetoftaxattributabletononcontrollinginterest": 9000,
    "comprehensiveincomenetoftax": -10784000,
    "earningspersharebasicanddiluted": -0.66,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 15764829,
    "sharesoutstanding": 15028536,
    "cumulativeeffectofnewaccountingprincipleinperiodofadoption1": -39000,
    "stockissuedduringperiodvaluesharebasedcompensation": 476000,
    "stockissuedduringperiodsharessharebasedcompensation": 23738,
    "stockbasedcompensationtoboardofdirectors": 208000,
    "stockbasedcompensationtoboardofdirectorsshares": 12609,
    "stockissuedduringperiodvalueconversionofconvertiblesecurities": 15668000,
    "stockissuedduringperiodsharesconversionofconvertiblesecurities": 1849749,
    "stockissuedduringperiodvalueissuedforservices": 125000,
    "stockissuedduringperiodsharesissuedforservices": 6062,
    "stockissuedduringperiodvaluestockoptionsexercised": 29000,
    "stockissuedduringperiodsharesstockoptionsexercised": 6000,
    "conversionoflipomedixbridgenotes": 283000,
    "othercomprehensiveincomeforeigncurrencytransactionandtranslationadjustmentnetoftaxportionattributabletoparent": -22000,
    "depreciationdepletionandamortization": 1866000,
    "deferredincometaxesandtaxcredits": 13000,
    "gainlossoninvestmentshedgefund": 2385000,
    "provisionfordoubtfulaccounts": 96000,
    "employeebenefitsandsharebasedcompensationnoncash": 684000,
    "amortizationofdebtdiscountpremium": 54000,
    "increasedecreaseinaccountsreceivable": -87000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -234000,
    "increasedecreaseinotheroperatingassets": 168000,
    "increasedecreaseinaccountspayableandaccruedliabilities": 713000,
    "increasedecreaseinothercurrentliabilities": 88000,
    "increasedecreaseinduetorelatedpartiescurrent": -65000,
    "increasedecreaseinduefromrelatedparties": -162000,
    "interestexpenserelatedparty": 19000,
    "increasedecreaseinotherliabilities": 82000,
    "netcashprovidedbyusedinoperatingactivities": -4666000,
    "purchaseofinvestmentinaltira": 500000,
    "paymentstoacquirepropertyplantandequipment": 534000,
    "netcashprovidedbyusedininvestingactivities": -1034000,
    "proceedsfromstockoptionsexercised": 29000,
    "paymentsfortaxesrelatedtoshareswithheldforemployeetaxes": -125000,
    "netcashprovidedbyusedinfinancingactivities": -96000,
    "effectofexchangerateoncashandcashequivalents": -22000,
    "cashandcashequivalentsperiodincreasedecrease": -5818000,
    "amountdueforacquiredroyaltyrights": 3500000,
    "transferofassetheldforsale": 2968000,
    "conversionoflipomedixbridgenote": 283000,
    "conversionofrelatedpartyconvertiblenotespayableandaccruedinterest": 15668000,
    "countryofincorporation": "Israel",
    "ownershipinterestinsubsidiary": 0.45,
    "finitelivedintangibleassetusefullife": "P5Y",
    "stockholderequityincludingportionattributabletononcontrollinginterest": -1147000,
    "hedgefunds": 7510000,
    "availableforsalesecurities": 7510000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassetvalue": 7510000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassetgainlossincludedinearnings1": 2385000,
    "accountsreceivablegross": 364000,
    "accountsreceivablerelatedpartiescurrent": 121000,
    "allowancefordoubtfulaccountsreceivable": 218000,
    "accountsreceivablenet": 267000,
    "buildingsandimprovementsgross": 47591000,
    "land": 10412000,
    "furnitureandfixturesgross": 1145000,
    "propertyplantandequipmentother": 256000,
    "propertyplantandequipmentgross": 59404000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 14971000,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -10239000,
    "incomelossfromcontinuingoperationsbeforeincometaxesforeign": -704000,
    "incomelossfromcontinuingoperationsbeforeincometaxesminorityinterestandincomelossfromequitymethodinvestments": -10943000,
    "currentforeigntaxexpensebenefit": -2000,
    "currentfederaltaxexpensebenefit": -9000,
    "currentincometaxexpensebenefit": -11000,
    "deferredforeignincometaxexpensebenefit": -18000,
    "deferredincometaxexpensebenefit": -18000,
    "incometaxexpensebenefits": -29000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": 2298000,
    "incometaxreconciliationstateandlocalincometaxes": 662000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": -3007000,
    "incometaxreconciliationforeignincometaxratedifferential": 11000,
    "incometaxreconciliationotheradjustments": -2000,
    "incometaxreconciliationotherreconcilingitems": 9000,
    "deferredtaxassetsoperatinglosscarryforwards": 8395000,
    "deferredtaxassetstaxcreditcarryforwardsalternativeminimumtax": 2660000,
    "deferredtaxassetstaxdeferredexpensereservesandaccruals": 61000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 312000,
    "deferredtaxassetsgross": 11428000,
    "deferredtaxassetsvaluationallowance": 11422000,
    "deferredtaxassetsnet": 6000,
    "deferredtaxassetsliabilitiesnet": 6000,
    "operatingleasesfutureminimumpaymentsremainderoffiscalyear": 2857000,
    "operatingleasesfutureminimumpaymentsdueintwoyears": 2855000,
    "operatingleasesfutureminimumpaymentsdueinthreeyears": 2709000,
    "operatingleasesfutureminimumpaymentsdueinfouryears": 2693000,
    "operatingleasesfutureminimumpaymentsdueinfiveyears": 2209000,
    "operatingleasesfutureminimumpaymentsduethereafter": 1948000,
    "operatingleasesfutureminimumpaymentsdue": 15271000,
    "operatingincomeloss1": -8465000,
    "concentrationriskpercentage1": 0.06,
    "noncurrentassets": 44433000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 580874,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 2846000,
    "stockissuedduringperiodsharestocksoptionsexercised": -6000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiod": 259,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionoutstandingweightedaverageremainingcontractualterm2": "P2Y237D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 580874,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P2Y237D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 2846000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 123104,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestedweightedaveragegrantdatefairvalue": 10.8,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiod": 478000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 19.87,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiod": 57060,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionvestedinperiodweightedaveragegrantdatefairvalue": -8.17,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeitedinperiod": 333,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeituresweightedaveragegrantdatefairvalue": 4.9,
    "othercomprehensiveincomelossreclassificationadjustmentfromaocionderivativesnetoftax": 580874,
    "ownershipinterestinsubsidiaries": 0.9,
    "debtinstrumentinterestratestatedpercentage": 0.45,
    "interestanddebtexpense": 96000,
    "concentrationriskpercentage": 0.5,
    "percentageofconsolidationlessthanwhollyownedsubsidiaryparentownershipinterestchangespurchaseofinterestbyparent": 0.9,
    "potentialownershippurchase": 0.5,
    "indirectinterestassetspercentage": 0.45,
    "exercisepriceofwarrantsorrightsdescription": "Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the &#x201c;Warrant&#x201d;). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share",
    "purchaseofexercisewarrantshares": 16700000,
    "fullydiluted": 0.1,
    "bonusshares": 0.37,
    "investments": 4000000,
    "businesscombinationcontingentconsiderationliabilitycurrent": 6000000,
    "equitymethodinvestments": 500000,
    "investmentrelatedliabilities": 3500000,
    "percentageofissuedandoutstandingshares": 0.12,
    "proceedsfrominterestreceived": 192000,
    "lineofcreditfacilityinterestrateduringperiod": 0.375,
    "fairvalueestimatenotpracticablecostmethodinvestment": 2000000,
    "unrealizedlossonsecurities": 800000,
    "depreciation": 1900000,
    "federalstatutorycorporatetaxdescription": "The Tax Act provides for comprehensive tax legislation that, among other things, reduces the U.S. federal statutory corporate tax rate from 35.0% to 21.0% effective January 1, 2018, broadens the U.S. federal income tax base, requires companies to pay a one-time repatriation tax on earnings of certain foreign subsidiaries that were previously tax deferred (&#x201c;transition tax&#x201d;), and creates new taxes on certain foreign sourced earnings.",
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 32700000,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 13600000,
    "deferredtaxassetsoperatinglosscarryforwardsforeign": 2400000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.8,
    "descriptionofnetoperatingloss": "The federal NOL carryforwards generated prior to 2018 will begin to expire in 2026. The state NOLs will begin to expire in 2038 and foreign NOLs do not expire.",
    "legalfees": 225000,
    "debtinstrumentconvertiblebeneficialconversionfeature": 70000,
    "amortizationoffinancingcostsanddiscounts": 16000,
    "duetorelatedpartiescurrentandnoncurrent": 309000,
    "duefromrelatedparties": 480000,
    "areaofland": 3600,
    "duetootherrelatedpartiesnoncurrent": 120000,
    "subsidiaryorequitymethodinvesteeownershippercentagedescription": "The Company has recognized approximately $192 thousand and $0 in income from it&#x2019;s ownership interests of 37.5% in RP Finance for the years ended July 31, 2020 and 2019, respectively (see Note 4).",
    "percentageoftotalrevenue": 0.52,
    "leaseexpirationdates": "The Company is the lessor of certain properties which are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2029.",
    "otherincome": 3600000,
    "percentageofrelatedparties": 0.52,
    "relatedpartyleasesexpiredescription": "The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, Newark, New Jersey, and (ii) 3,595 square feet in Israel.",
    "leaseandrentalexpense": 2000000,
    "numberofreportablesegments": 2,
    "numbetofnonemployeedirectors": 3,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorized": 1064048,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 626662,
    "sharesissuedpricepershare": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingrights": "Option awards generally vest on a graded basis over five years of service and have 10-year contractual terms.",
    "stockissuedduringperiodsharesrestrictedstockawardgross": 92690,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P2Y127D",
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedstockoptions": 1300000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiodtotalfairvalue": 466000,
    "descriptionofpurchaseagreementperiodicpayments": "In August 2020, Rafael Pharmaceuticals called for a $5 million draw on the line of credit facility and the facility was funded by RP Finance in the amount $5 million, in August 2020 and September 2020. The Company funded $1,875,000 in accordance with its 37.5% ownership interests in RP Finance.",
    "entityregistrantname": "Rafael Holdings, Inc.",
    "documenttype": "10-K",
    "currentfiscalyearenddate": "--07-31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1713863,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2020-07-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityshellcompany": "false",
    "entityextransitionperiod": "false",
    "entityfilenumber": "000-55863",
    "entityincorporationstatecountrycode": "DE",
    "entityinteractivedatacurrent": "Yes"
  },
  {
    "date": "2019-07-30",
    "symbol": "RFL",
    "period": "FY",
    "entityregistrantname": "Rafael Holdings, Inc.",
    "entitycentralindexkey": 1713863,
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--07-31",
    "documenttype": "10-K",
    "documentperiodenddate": "2019-07-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2019,
    "entityfilercategory": "Accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entitysmallbusiness": "true",
    "entityextransitionperiod": "false",
    "entityemerginggrowthcompany": "true",
    "entityfilenumber": "000-55863",
    "entityshellcompany": "false",
    "entityincorporationstatecountrycode": "DE",
    "cashandcashequivalentsatcarryingvalue": 12024000,
    "receivablesnetcurrent": 450000,
    "duefromrelatedpartiescurrent": 280000,
    "prepaidexpenseandotherassetscurrent": 34000,
    "assetscurrent": 13261000,
    "propertyplantandequipmentnet": 48733000,
    "longterminvestments": 70018000,
    "otherlongterminvestments": 2000000,
    "investmentshedgefunds": 5125000,
    "deferredtaxassetsnetnoncurrent": 19000,
    "inprocessresearchanddevelopment": 1575000,
    "otherassetsnoncurrent": 1400000,
    "assets": 3608000,
    "accountspayablecurrent": 795000,
    "accruedliabilitiescurrent": 605000,
    "otherliabilitiescurrent": 27000,
    "liabilitiescurrent": 1427000,
    "duetorelatedpartiesnoncurrent": 65000,
    "convertibledebtnoncurrent": 14946000,
    "otherliabilitiesnoncurrent": 292000,
    "longtermnotespayable": 649000,
    "liabilities": 17379000,
    "commonstockvalue": 131000,
    "additionalpaidincapital": 112898000,
    "retainedearningsaccumulateddeficit": -5840000,
    "accumulatedothercomprehensiveincomelossnetoftax": 3784000,
    "stockholdersequity": 131000,
    "minorityinterest": 13783000,
    "stockholdersequityincludingportionattributabletononcontrollinginterest": 13783000,
    "liabilitiesandstockholdersequity": 142143000,
    "allowancefordoubtfulaccountsreceivablecurrent": 122000,
    "convertiblenotediscountamountforrelatedparty": 54000,
    "commonstockparorstatedvaluepershare": 0.01,
    "commonstocksharesauthorized": 200000000,
    "commonstocksharesissued": 13142502,
    "commonstocksharesoutstanding": 13142502,
    "operatingleasesincomestatementleaserevenue": 1452000,
    "revenuefromrelatedparties": 1800000,
    "parkingrevenues": 874000,
    "revenuesotherrelatedparty": 480000,
    "revenues": 4931000,
    "sellinggeneralandadministrativeexpense": 440000,
    "researchanddevelopmentexpense": 1027000,
    "depreciationandamortization": 1779000,
    "operatingincomeloss": -5083000,
    "interestincomeexpensenet": 469000,
    "foreigncurrencytransactiongainlossbeforetax": 47000,
    "gainlossoninvestments": 330000,
    "unrealizedgainoninvestmentshedgefund": -907000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -4943000,
    "incometaxexpensebenefit": -19000,
    "profitloss": -231000,
    "netincomelossattributabletononcontrollinginterest": -231000,
    "netincomeloss": -4693000,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": 298000,
    "comprehensiveincomenetoftaxincludingportionattributabletononcontrollinginterest": -4626000,
    "comprehensiveincomenetoftaxattributabletononcontrollinginterest": -173000,
    "comprehensiveincomenetoftax": -4453000,
    "earningspersharebasicanddiluted": -0.35,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 13275239,
    "sharesoutstanding": 13142502,
    "cumulativeeffectofnewaccountingprincipleinperiodofadoption1": 39000,
    "stockissuedduringperiodvaluesharebasedcompensation": 1000,
    "stockissuedduringperiodsharessharebasedcompensation": 74637,
    "stockissuedduringperiodvaluestockoptionsexercised": 190000,
    "stockissuedduringperiodsharesstockoptionsexercised": 38710,
    "stockissuedduringperiodsharesrestrictedstockawardgross": 92690,
    "stockissuedduringperiodvaluepurchaseofassets": 12000,
    "stockissuedduringperiodsharespurchaseofassets": 1254200,
    "stockissueduringperiodvaluestockbasedcompensationtoboardofdirectors": 107000,
    "stockbasedcompensationtoboardofdirectorsshares": 12609,
    "stockissuedduringperiodvaluedebtdiscountonconvertibledebt": 71000,
    "stockissueduringperiodvaluecapitalcontributionfornoncontrollinginterest": 4587000,
    "othercomprehensiveincomeforeigncurrencytransactionandtranslationadjustmentnetoftaxportionattributabletoparent": -298000,
    "depreciationdepletionandamortization": 1779000,
    "deferredincometaxesandtaxcredits": -19000,
    "interestincomeonseriesconvertiblenotes": -848000,
    "incomelossfromequitymethodinvestmentsnetofdividendsordistributions": 37000,
    "marketablesecuritiesgainloss": 330000,
    "gainlossoninvestmentshedgefund": 907000,
    "provisionfordoubtfulaccounts": 40000,
    "employeebenefitsandsharebasedcompensationnoncash": 372000,
    "amortizationofdebtdiscountpremium": 17000,
    "increasedecreaseinaccountsreceivable": 285000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 86000,
    "increasedecreaseinintangibleassetscurrent": -76000,
    "increasedecreaseinotheroperatingassets": -275000,
    "increasedecreaseinaccountspayableandaccruedliabilities": 533000,
    "increasedecreaseinothercurrentliabilities": 3000,
    "increasedecreaseinduetorelatedparties": 654000,
    "increasedecreaseinduefromrelatedparties": 280000,
    "increasedecreaseinaccruedliabilities": 649000,
    "increasedecreaseinotheroperatingliabilities": 104000,
    "netcashprovidedbyusedinoperatingactivities": -3132000,
    "paymentstoacquirepropertyplantandequipment": 399000,
    "proceedsfromsaleandmaturityofmarketablesecurities": 25031000,
    "paymentstoacquireotherinvestments": 55870000,
    "netcashprovidedbyusedininvestingactivities": -31238000,
    "proceedsfromminorityshareholders": 4587000,
    "proceedsfromrepaymentsofdebt": 3335000,
    "proceedsfromissuanceorsaleofequity": 7777000,
    "proceedsfromstockoptionsexercised": 190000,
    "proceedsfromconvertibledebt": 15000000,
    "netcashprovidedbyusedinfinancingactivities": 30889000,
    "effectofexchangerateoncashandcashequivalents": -298000,
    "cashandcashequivalentsperiodincreasedecrease": -3779000,
    "adoptioneffectofnoncashfinancingandinvestingactivities": 39000,
    "beneficialconversionfeatureofconvertibledebtrelatedparty": 71000,
    "debtandaccruedinterestconvertedtopreferredstock": 10848000,
    "relatedpartydepositutilizedtopurchasecommonshares": 864000,
    "countryofincorporation": "Israel",
    "ownershipinterestinsubsidiary": 0.45,
    "finitelivedintangibleassetusefullife": "P7Y",
    "stockholderequityincludingportionattributabletononcontrollinginterest": 4082000,
    "concentrationriskpercentage1": 0.03,
    "numberofcustomer": 5,
    "interestincomeother": 333000,
    "percentageofconsolidationlessthanwhollyownedsubsidiaryparentownershipinterestchangespurchaseofinterestbyparent": 0.1,
    "potentialownershippurchase": 0.9,
    "investmentwarrantsexpirationdate1": "2020-12-31",
    "proceedsfromsaleofequitymethodinvestments": 525000,
    "indirectinterestassetspercentage": 0.45,
    "exercisepriceofwarrantsorrightsdescription": "IDT-Rafael Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase ownership to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share.",
    "purchaseofexercisewarrantshares": 16700000,
    "fullydiluted": 0.51,
    "bonusshares": 0.38,
    "proceedsfromsaleandmaturityofavailableforsalesecurities": 25000000,
    "availableforsalesecuritiesgrossrealizedgains": 330000,
    "hedgefunds": 5125000,
    "availableforsalesecurities": 5125000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassetvalue": 5125000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassettransfersnet": -7900000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisassetgainlossincludedinearnings1": 907000,
    "fairvalueestimatenotpracticablecostmethodinvestment": 2000000,
    "accountsreceivablegross": 561000,
    "accountsreceivablerelatedpartiescurrent": 11000,
    "allowancefordoubtfulaccountsreceivable": 122000,
    "accountsreceivablenet": 450000,
    "buildingsandimprovementsgross": 54241000,
    "land": 10412000,
    "furnitureandfixturesgross": 1145000,
    "propertyplantandequipmentother": 255000,
    "propertyplantandequipmentgross": 66053000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 17320000,
    "costmethodinvestments": 100000,
    "minorityinterestperiodincreasedecrease": 559000,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -3410000,
    "incomelossfromcontinuingoperationsbeforeincometaxesforeign": -1533000,
    "incomelossfromcontinuingoperationsbeforeincometaxesminorityinterestandincomelossfromequitymethodinvestments": -4943000,
    "deferredforeignincometaxexpensebenefit": -19000,
    "deferredincometaxexpensebenefit": -19000,
    "incometaxexpensebenefits": -19000,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -908000,
    "incometaxreconciliationstateandlocalincometaxes": -172000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": -30000,
    "incometaxreconciliationforeignincometaxratedifferential": -24000,
    "incometaxreconciliationotheradjustments": 102000,
    "incometaxreconciliationprioryearincometaxes": 1030000,
    "incometaxreconciliationotherreconcilingitems": -17000,
    "deferredtaxassetsoperatinglosscarryforwards": 5316000,
    "deferredtaxassetstaxcreditcarryforwardsalternativeminimumtax": 2692000,
    "deferredtaxassetstaxdeferredexpensereservesandaccruals": 34000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 119000,
    "deferredtaxassetsgross": 8161000,
    "deferredtaxassetsvaluationallowance": 8142000,
    "deferredtaxassetsnet": 19000,
    "deferredtaxassetsliabilitiesnet": 19000,
    "federalstatutorycorporatetaxdescription": "The Tax Act provides for comprehensive tax legislation that, among other things, reduces the U.S. federal statutory corporate tax rate from 35.0% to 21.0% effective January 1, 2018, broadens the U.S. federal income tax base, requires companies to pay a one-time repatriation tax on earnings of certain foreign subsidiaries that were previously tax deferred (\"transition tax\"), and creates new taxes on certain foreign sourced earnings.",
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 22300000,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 3200000,
    "deferredtaxassetsoperatinglosscarryforwardsforeign": 1200000,
    "operatinglosscarryforwardsexpirationdate": "2038-07-31",
    "debtinstrumentfaceamount": 15000000,
    "debtinstrumentunamortizeddiscount": 54000,
    "debtinstrumentconvertiblebeneficialconversionfeature": 70000,
    "amortizationoffinancingcostsanddiscounts": 16000,
    "interestexpensedebt": 650000,
    "duetorelatedpartiescurrentandnoncurrent": 60000,
    "duefromrelatedparties": 218000,
    "leasesofficespacechargedescription": "The Company charges Genie $23.46 per square foot annually for approximately 8,631 square feet of space.",
    "operatingleasesfutureminimumpaymentsduecurrent": 1054000,
    "operatingleasesfutureminimumpaymentsdueintwoyears": 1136000,
    "operatingleasesfutureminimumpaymentsdueinthreeyears": 993000,
    "operatingleasesfutureminimumpaymentsdueinfouryears": 630000,
    "operatingleasesfutureminimumpaymentsdueinfiveyears": 1185000,
    "operatingleasesfutureminimumpaymentsduethereafter": 3468000,
    "operatingleasesfutureminimumpaymentsdue": 8466000,
    "leaseexpirationdates": "Dates ranging from 2021 to 2030.",
    "relatedpartyleasesexpiredescription": "The Company has related party leases that expire in April 2025, for (i) an aggregate of 88,631 square feet, and which includes two parking spots per thousand square feet of space leased at 520 Broad Street, and (ii) 3,595 square feet in Israel.",
    "leaseandrentalexpense": 2000000,
    "noncurrentassets": 1637000,
    "numberofreportablesegments": 2,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 587133,
    "stockissuedduringperiodsharestocksoptionsexercised": 38710,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiod": 819,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 572934,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 4.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P3Y7M28D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P3Y7M28D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 2877000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 2807000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 156426,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiod": 70718,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiod": 60010,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestedweightedaveragegrantdatefairvalue": 10.41,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 16.49,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiodweightedaveragegrantdatefairvalue": 4.96,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedsharebasedawardsotherthanoptions": 1200000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingrights": "Option awards generally vest on a graded basis over five years of service and have ten-year contractual terms.",
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiodtotalfairvalue": 298000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P3Y",
    "fairvalueofawardsondateofgrantincludedinsellinggeneralandadministrativeexpense": 107000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardrestrictedsharesvestingexpectedterm": "P2Y",
    "restrictedsharesatfairvalue": 1200000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 587133
  }
]